A 48-week open-label, non-comparative, multi-centre, phase IIIb study to evaluate the efficacy and safety of the lipid-regulating agent rosuvastatin in the treatment of subjects with Fredrickson type IIa and type IIb dyslipidaemia, including heterozygous familial hypercholesterolaemia.
Phase of Trial: Phase III
Latest Information Update: 29 May 2009
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 27 Mar 2006 New trial record.